文献速递白血病MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

来那度胺联合阿扎胞苷:异基因干细胞移植后复发急性髓系白血病患者的新型挽救治疗

Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia.
PubMed 文献 · J Clin Oncol · 2019-01-17

该研究纳入29例异基因干细胞移植后复发的急性髓系白血病(n=24)或骨髓增生异常综合征(n=5)患者,采用阿扎胞苷75 mg/m²×7天后序贯来那度胺剂量递增(第10-30天),以改良贝叶斯连续再评估法确定最大耐受剂量。来那度胺最大耐受剂量为每日25 mg,3例发生2-4级移植物抗宿主病,无移植物抗宿主病相关死亡,15例可评估患者中7例(47%)获主要临床反应。

要点

  • 移植后来那度胺联合阿扎胞苷的最大耐受剂量为来那度胺每日25 mg。
  • 3例发生2-4级移植物抗宿主病,无移植物抗宿主病相关死亡。
  • 15例可评估患者中7例(47%)获主要临床反应。

核心结论

  • 来那度胺可在异基因移植后与阿扎胞苷联合安全给药,该联合在复发急性髓系白血病/骨髓增生异常综合征中显示临床活性,但未逆转T细胞耗竭的生物学特征。
  • 联合来那度胺/阿扎胞苷是异基因移植后复发患者的一种新型且有活性的挽救治疗。

研究设计与样本

  • 29例异基因干细胞移植后复发的急性髓系白血病(n=24)或骨髓增生异常综合征(n=5)患者接受序贯阿扎胞苷75 mg/m²×7天,随后第10-30天来那度胺剂量递增。
  • 剂量分配和最大耐受剂量估计采用改良贝叶斯连续再评估法指导。

主要发现

  • 序贯阿扎胞苷和来那度胺治疗耐受良好,移植后来那度胺联合阿扎胞苷的最大耐受剂量确定为每日25 mg。
  • 3例发生2-4级移植物抗宿主病,无移植物抗宿主病相关死亡。
  • 15例可评估患者中7例(47%)在来那度胺/阿扎胞苷治疗后获主要临床反应。
  • 复发时CD8+ T细胞干扰素-γ/肿瘤坏死因子-α产生受损,来那度胺/阿扎胞苷给药期间未逆转。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Salvage options for patients who relapse after allogeneic stem-cell transplantation (allo-SCT) for acute myeloid leukemia (AML) and myelodysplasia (MDS) remain limited, and novel treatment strategies are required. Both lenalidomide (LEN) and azacitidine (AZA) possess significant antitumor activity effect in AML. Administration of LEN post-transplantation is associated with excessive rates of graft-versus-host disease (GVHD), but AZA has been shown to ameliorate GVHD in murine transplantation models. We therefore examined the tolerability and activity of combined LEN/AZA administration in post-transplantation relapse. PATIENTS AND METHODS: Twenty-nine patients who had relapsed after allo-SCT for AML (n = 24) or MDS (n = 5) were treated with sequential AZA (75 mg/m2 for 7 days) followed by escalating doses of LEN on days 10 to 30. Dose allocation and maximum tolerated dose (MTD) estimation were guided by a modified Bayesian continuous reassessment method (CRM). RESULTS: Sequential AZA and LEN therapy was well tolerated. The MTD of post-transplantation LEN, in combination with AZA, was determined as 25 mg daily. Three patients developed grade 2 to 4 GVHD. There was no GVHD-related mortality. Seven of 15 (47%) patients achieved a major clinical response after LEN/AZA therapy. CD8+ T cells demonstrated impaired interferon-γ/tumor necrosis factor-α production at relapse, which was not reversed during LEN/AZA administration. CONCLUSION: We conclude LEN can be administered safely post-allograft in conjunction with AZA, and this combination demonstrates clinical activity in relapsed AML/MDS without reversing biologic features of T-cell exhaustion. The use of a CRM model delivered improved efficiency in MTD assessment and provided additional flexibility. Combined LEN/AZA therapy represents a novel and active salvage therapy in patients who had relapsed post-allograft.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Craddock C, Slade D, De Santo C, et al. Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia. J Clin Oncol. 2019. PMID: 30653424. doi:10.1200/JCO.18.00889

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。